NDAORALTABLETPriority Review
Approved
May 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
9
Data completeness
6/8 — Strong
Priority Review
CHANTIX (varenicline tartrate) by Pfizer is α4β2 neuronal nicotinic acetylcholine receptors. Approved for smoking cessation, tobacco use disorder. First approved in 2006.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CHANTIX (varenicline tartrate) is an oral small-molecule medication approved in 2006 for smoking cessation and tobacco use disorder. It works by selectively binding to α4β2 neuronal nicotinic acetylcholine receptors, providing partial agonist activity while blocking nicotine's ability to stimulate reward pathways in the brain. This dual mechanism reduces both cravings and the rewarding effects of smoking.
$0.088MPart D
LOE ApproachingDeclining
As an LOE-approaching product with modest spending, teams are likely consolidating functions and focusing on lifecycle extension rather than primary growth initiatives.
Mechanism of Action
α4β2 neuronal nicotinic acetylcholine receptors. The efficacy of CHANTIX in smoking cessation is believed to be the result of varenicline's activity at α4β2 sub-type of the nicotinic receptor where its binding produces agonist activity, while simultaneously preventing nicotine binding to these…
Indications (2)
Worked on CHANTIX at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.